Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.

Scientific reports - 11 Dec 2023

Burdett Nikki L, Willis Madelynne O, Pandey Ahwan, Fereday Sian, DeFazio Anna, Bowtell David D L, Christie Elizabeth L

Abstract excerpt

While the introduction of poly-(ADP)-ribose polymerase (PARP) inhibitors in homologous recombination DNA repair (HR) deficient high grade serous ovarian, fallopian tube and primary peritoneal cancers (HGSC) has improved patient survival, resistance to PARP inhibitors frequently occurs. Preclinical and translational studies have identified multiple mechanisms of resistance; here we examined tumour samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 Protein

Share to Mutation

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38072854
DOI: 10.1038/s41598-023-48153-x
PMCID: PMC10711013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer.PMID 38072854Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

BRCA1/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challengesSemantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancerSemantic proximity Read ↗

Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancerSemantic proximity Read ↗

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell linesSemantic proximity Read ↗

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome ResistanceSemantic proximity Read ↗

Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future OptionsSemantic proximity Read ↗

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer CellsSemantic proximity Read ↗

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Semantic proximity Read ↗

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian CarcinomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.